“We have signals of effect in all three dose levels, and see quite rapid effects in the eyes of some patients”, says CEO Anders Haegerstrand.
See the full interview with CEO Anders Haegerstrand and CMO/CFO Anna Frostegård below:
This material has been prepared for marketing purposes and is not and should not be considered to constitute a prospectus under applicable laws and regulations. The full terms and conditions of the rights issue and further information about the company have been set out in a information document which has been made public and published on the said company's website.